FRMD6-AS1

Summary

FRMD6-AS1 (FRMD6 antisense RNA 1, HGNC:20129) is a long non-coding RNA gene on chromosome 14q22.1.

At a glance

• GWAS associations: 2

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20129
Approved symbol	FRMD6-AS1
Name	FRMD6 antisense RNA 1
Location	14q22.1
Locus type	RNA, long non-coding
Status	Approved
Ensembl gene	ENSG00000273888
Entrez	145438
RNAcentral	URS000075DA22 — lncRNA, 2246 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 0

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

None — 0 exons

Expression profiles

Bgee: expression breadth ubiquitous, 188 present calls, max score 85.67.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.3287 / max 5.8683, expressed in 177 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
143201	0.1962	80
143202	0.1325	46

Top tissues by expression

227 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.67	gold quality
cartilage tissue	UBERON:0002418	73.13	gold quality
buccal mucosa cell	CL:0002336	71.37	gold quality
tibia	UBERON:0000979	71.24	gold quality
pancreatic ductal cell	CL:0002079	67.34	silver quality
cauda epididymis	UBERON:0004360	67.21	gold quality
caput epididymis	UBERON:0004358	67.01	gold quality
corpus epididymis	UBERON:0004359	66.90	gold quality
mammary duct	UBERON:0001765	63.53	silver quality
epithelium of mammary gland	UBERON:0003244	63.48	silver quality
endothelial cell	CL:0000115	62.98	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	62.31	gold quality
stromal cell of endometrium	CL:0002255	62.17	gold quality
body of uterus	UBERON:0009853	61.62	gold quality
sural nerve	UBERON:0015488	61.35	silver quality
seminal vesicle	UBERON:0000998	60.98	gold quality
skin of hip	UBERON:0001554	60.64	gold quality
cortical plate	UBERON:0005343	60.08	gold quality
lower lobe of lung	UBERON:0008949	59.40	silver quality
Brodmann (1909) area 46	UBERON:0006483	59.33	silver quality
myometrium	UBERON:0001296	59.05	gold quality
postcentral gyrus	UBERON:0002581	59.03	silver quality
trabecular bone tissue	UBERON:0002483	58.54	silver quality
mammalian vulva	UBERON:0000997	58.44	silver quality
mammary gland	UBERON:0001911	58.43	gold quality
parietal lobe	UBERON:0001872	58.38	silver quality
thoracic mammary gland	UBERON:0005200	57.98	gold quality
layer of synovial tissue	UBERON:0007616	57.77	gold quality
hindlimb stylopod muscle	UBERON:0004252	57.66	silver quality
placenta	UBERON:0001987	57.62	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.32

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 1)

• LncRNA FRMD6-AS1 promotes hepatocellular carcinoma cell migration and stemness by regulating SENP1/HIF-1alpha axis. (PMID:36827886)

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

Putative uncharacterized protein FRMD6-AS1 — P0C7T7 (reviewed: P0C7T7)

Alternative names: FRMD6 antisense RNA 1, FRMD6 antisense gene protein 1

All UniProt accessions (0):

UniProt curated annotations — full annotation on UniProt →

RefSeq proteins (0): (*=MANE)

Domains & families (InterPro)

UniProt features (5 total): compositionally biased region 2, chain 1, region of interest 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P0C7T7-F1	37.05	0.00

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (0):

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

0 interactions, top by confidence:

ESM2 similar proteins: A0A3Q1LFG5, A6NHQ4, A8MZ25, B3EWF7, C0HMD6, H3BQW9, I0J062, I3L1E1, P0C7T7, P0C7V0, P0C864, P0C879, P0C880, P0DP75, P70339, Q495Z4, Q5T4H9, Q5TG53, Q66K80, Q6EEV4, Q6UXQ8, Q6UXU0, Q6ZRN7, Q6ZS46, Q6ZSR3, Q6ZUF6, Q71F78, Q7TNS8, Q86X59, Q8JN06, Q8N319, Q8N6K4, Q8N6U2, Q8N7H1, Q8N7Y1, Q8N910, Q8N9P0, Q8N9X3, Q8NAQ8, Q8NBZ9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

0 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000627388 (14:51653027 T>C), RS1000676824 (14:51653226 C>T), RS1000691183 (14:51650081 T>C), RS1001468827 (14:51650620 C>A,T), RS1001577980 (14:51652478 C>T), RS1001918112 (14:51650836 G>C), RS1003186398 (14:51651719 G>A), RS1003250602 (14:51651533 C>T), RS1003544771 (14:51651497 G>A), RS1003854353 (14:51651373 G>C,T), RS1003906713 (14:51651468 C>A,T), RS1003949310 (14:51651766 G>C,T), RS1004861747 (14:51650465 G>A,C), RS1004912674 (14:51650605 C>T), RS1004920688 (14:51652913 G>A)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST009615_14	Triglyceride levels x loop diuretics use interaction	3.000000e-07
GCST009615_15	Triglyceride levels x loop diuretics use interaction	6.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004530	triglyceride measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

7 total (human), top 7 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	3
perfluorooctane sulfonic acid	decreases expression	1
ICG 001	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Smoke	decreases expression	1
Thiram	decreases expression	1
Lactic Acid	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.